Akari Therapeutics, Plc AKTX
As ofNov 16, 2026, 1:30 PM EST
- YTD
- -43.69%
- 1 year
- -69.23%
- Market cap
- 14.92M
- Shares out
- 26.47M
- Forward P/E
- -0.29
- YTD return
- -43.69%
- 1-year return
- -69.23%
- 50-day average
- 1.78
- 200-day average
- 2.41
- Volume
- 13.14K
- Avg volume
- 62.08K
- Open
- 6.98
- Previous close
- 6.80
- Day's range
- 6.35 – 7.05
- 52-week range
- 3.02 – 29.32
- Beta
- 0.95
5D -0.81 (-10.64%)
Key statistics
- Enterprise value
- 35.14B
- Free cash flow
- -7.51M
- Total cash
- 4.18M
- Total debt
- 1.00M
- Short % of float
- 0.23%
Fundamental scorecard
4 of 25 checks passed on AKTX’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 6, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Oct 3, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| Jul 19, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| May 15, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Jan 6, 2023 | Sep 1, 2022 | 0.00 | — | — | — |
| Sep 27, 2022 | Jun 1, 2022 | 0.00 | -2.00 | — | — |
About Akari Therapeutics, Plc
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- akaritx.com
News
Akari Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated ADC Payload Platform
Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho
12 Health Care Stocks Moving In Monday's Pre-Market Session
Why XCF Global Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on AKTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DICICCO WENDY FRANCES | Chief Financial Officer | Stock Award(Grant) | Apr 30, 2024 | 158,474,000 |
| PATEL SAMIR RASHMIKANT | Director | Stock Award(Grant) | Jun 27, 2024 | 3,502,890,000 |
| PRUDO-CHLEBOSZ RAYMOND M.D. | Director | Stock Award(Grant) | Dec 1, 2024 | 4,916,600,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Omnia Family Wealth, LLC | 0.33% | 87,628 | 85.88K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.13% | 33,260 | 32.59K | Sep 29, 2024 |
| Cerity Partners LLC | 0.09% | 23,643 | 23.17K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.07% | 18,069 | 17.71K | Sep 29, 2024 |
| Cresset Asset Management, LLC | 0.07% | 18,408 | 18.04K | Sep 29, 2024 |
| Cornerstone Planning Group LLC | 0.00% | 5 | 4 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.01% | 1,512 | 1.48K | Oct 30, 2024 |
